iRhythm Technologies reported a significant Q3 revenue miss and flat Zio AT sales, while also announcing a delay in its next-generation Zio MCT device FDA submission. These disclosures, attributed to post-acquisition integration challenges, led to a substantial decline in the company's share price and triggered an investor investigation.
iRhythm Technologies (IRTC) announced disappointing Q3 2026 financial results, missing analyst revenue estimates and reporting flat year-over-year sales for its key Zio AT product. Compounding these issues, the company revealed a delay in the FDA submission for its next-generation Zio MCT device until 2027, citing integration challenges from its VitalConnect acquisition. This confluence of negative news, including underperformance and a delayed product pipeline, has significantly impacted investor confidence, leading to a sharp decline in share price and prompting a potential securities investigation. For traders, this represents a clear negative catalyst, signaling potential short-term downside and long-term concerns regarding execution and growth prospects.